Outlook Therapeutics, Inc.
OTLKDrugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Aug 13, 2026
15dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
How OTLK's past catalysts played out
bevacizumab
Age-related Macular Degeneration
ranibizumab
Age-related Macular Degeneration
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
bevacizumab | Phase 3 | Age-related Macular Degeneration | - | |
ranibizumab | Phase 3 | Age-related Macular Degeneration | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Outlook Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Outlook Therapeutics, Inc.'s (OTLK) pipeline across Phase 3. Its lead program is bevacizumab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Outlook Therapeutics, Inc.'s next FDA catalyst?→
Outlook Therapeutics, Inc.'s (OTLK) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track OTLK biotech catalysts?→
Add OTLK to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Outlook Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.